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Paracoccidioidomycosis (PCM), one of the most important systemic mycoses in Central and South America,
is caused by the dimorphic fungus Paracoccidioides brasiliensis and has a high prevalence in Brazil. Glyco-
proteins of 43 and 70 kDa are the main antigenic compounds of P. brasiliensis and are recognized by Western
blotting by 100 and 96% of PCM patient sera, respectively. In the present study, an inhibition enzyme-linked
immunosorbent assay (ELISA) was used to detect gp70 in different biological samples from patients with PCM.
gp70 was detected in 98.76% of 81 serum samples, with an average concentration of 8.19 g/ml. The test was
positive for 100% of the patients with the acute and chronic unifocal forms of PCM and 98.43% of the patients
with the multifocal chronic form, with average concentrations of 11.86, 4.83, and 7.87 g/ml, respectively.
Bronchoalveolar lavage fluid from 23 patients with pulmonary unifocal PCM and 14 samples of cerebrospinal
fluid from patients with neurological PCM were also tested for gp70 detection, with the test showing 100%
sensitivity and 100% specificity, with mean gp70 concentrations of 7.5 and 6.78 g/ml, respectively. To
investigate the potential of gp70 detection by inhibition ELISA for the follow-up of PCM patients during
antimycotic therapy with itraconazole (ITZ), the sera of 23 patients presenting with the chronic multifocal form
of PCM were monitored at regular intervals of 1 month for 12 months. The results showed a decrease in
circulating gp70 levels during treatment which paralleled the reduction in anti-P. brasiliensis antibody levels.
The detection of P. brasiliensis gp70 from the biological fluids of patients suspected of having PCM proved to
be a promising method for diagnosing infection and evaluating the efficacy of ITZ treatment.
Paracoccidioidomycosis (PCM), the most prevalent systemic
fungal mycosis in Latin America, is caused by Paracoccidioides
brasiliensis , a thermally dimorphic fungus (5, 34). Different
clinical forms of the disease result from the interaction of
different P. brasiliensis strains with the host, a phenomenon
that may be related to the virulence of the infecting strain.
Some investigators (21, 37, 38, 41) believe that the mechanism
of virulence is determined by chemical components present on
the fungal wall, but others contest this explanation (44). Diag-
nosis of PCM is usually based on the demonstration of mul-
tibudding yeast cells in different biological specimens or the
detection of specific antibodies by histopathology or culture.
During the past decade, substantial progress has been made in
the development of innovative approaches and methods for
the serological diagnosis of PCM. Clinically relevant antigens
have been identified and adapted for use in immunoassays for
the detection of specific antibodies (12). Some investigators
have tried to detect circulating antigen in PCM patients using
polyvalent antigens or antibodies in different assays such as
competition enzyme-linked immunosorbent assay (ELISA)
(16), immunoradiometric assay (13), immunoelectrophoresis-
immunodiffusion (17), counterimmunoelectrophoresis (35),
passive hemagglutination inhibition (24), inverted linear im-
munoelectrophoresis (23), and immunoblotting (28); but all of
these assays presented low sensitivities. Go´mez et al. (19) were
the first to use monoclonal antibodies (MAbs) to detect the
87-kDa circulating antigen in PCM patients by inhibition
ELISA (inh-ELISA), which had 80.4% sensitivity. More re-
cently, the same technique was used to detect gp43 in serum,
cerebrospinal fluid (CSF), and bronchoalveolar lavage (BAL)
fluid of PCM patients with 95.1% sensitivity and 100% speci-
ficity (25) and to monitor PCM patients during azole treatment
(26).
The gp43 glycoprotein from P. brasiliensis is the main anti-
gen used for the diagnosis of PCM (32, 33, 40), being recog-
nized by virtually all sera from infected patients by different
serological methods (25, 27). Another important glycoprotein
expressed by the fungus is gp70, recognized by 96% of PCM
patient sera (3). gp70 is predominantly composed of polysac-
charides (27) and is able to induce proliferation of lymphocytes
from PCM patients (2). gp70 is also detected in the urine of
patients with the acute form of PCM (36). The treatment of
mice by injection of anti-gp70 MAb abolishes lung infection,
suggesting that gp70 may facilitate fungal installation and the
progression of lesions during the primary infection (27).
Detection of circulating antigens in patients with PCM has
proved to be useful not only for diagnostic purposes but also as
a tool to evaluate clearance of the fungal burden during treat-
ment. Go´mez et al. (19) reported on the use of the inh-ELISA
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to detect gp87 circulating antigen in sera from patients with
active disease and in patients receiving antimycotic therapy
(20). A previous study that used the same methodology was
able to detect gp43 in 96.29% of PCM patients, mainly in those
with the acute form of the disease (100%) (25). Moreover,
patients cleared this antigen during itraconazole (ITZ) ther-
apy, suggesting that this molecule may be used to assess the
host response to antifungal therapy.
When it is considered that, in addition to gp43, gp70 is an
important molecule in the P. brasiliensis system, in the present
study we investigated the application of gp70 antigen detection
in different biological specimens to obtain a diagnosis of PCM
as well as to assess antigen clearance during antifungal treat-
ment for disseminated disease.
MATERIALS AND METHODS
Clinical samples for PCM diagnosis. Blood specimens from a total of 81
patients with active PCM were taken at the time of the primary diagnosis. The
diagnosis of PCM was established for all patients by direct KOH examination,
isolation or the fungus by culture, and/or conventional positive serological tests.
Samples were collected from patients at different times between March 1990 and
December 2001. The samples were from patients seen at Hospital Sa˜o Paulo,
Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil; Hospital das Clínicas, Fed-
eral University of Parana´, Curitiba, Brazil; and Hospital das Clínicas, University
of Campinas, Campinas, Brazil. The 81 patients tested (73 males and 8 females)
were classified by their clinical presentations, as follows: 11 had the acute form
of PCM (mean age, 18.8 years) and 70 had the chronic form (mean age, 46.7
years), including 64 patients with multifocal disease and 6 with unifocal disease.
Biological material from 14 patients with neurological PCM (neuro-PCM) were
also tested, including 14 CSF samples and 11 serum samples, all of which were
obtained before treatment. In addition, 13 BAL fluid samples from patients with
pulmonary PCM were tested.
Serum samples from patients (n  71) with other mycologically and/or sero-
logically confirmed mycoses (51 serum samples from individuals with active
histoplasmosis and 20 individuals with cryptococcosis), obtained at the time of
diagnosis, were also evaluated. Ninety-three serum samples from healthy volun-
teers (blood donors), 6 CSF samples from patients with no fungal disease, and 10
BAL fluid samples from individuals with tuberculosis were included as negative
controls.
Clinical samples for monitoring of therapy. In order to evaluate the decrease
in the antigen concentration in response to antifungal therapy, a total of 23
patients with active PCM were evaluated. Sequential serum samples were ob-
tained from all selected patients, including one sample collected at the time of
diagnosis (baseline) and at least seven others collected during 8 to 12 months of
treatment. Samples were collected from patients attending the Infectious Dis-
eases Division, Hospital das Clínicas, Federal University of Parana´, between
2001 and 2002. The patients were males (mean age, 47.3 years) with the chronic
multifocal form of the disease who were successfully treated with ITZ. The good
clinical response to antifungal therapy exhibited by all selected patients was
characterized by the cessation of all clinical signs and symptoms related to the
infection, significant improvement in the chest X-ray pattern of pulmonary le-
sions, the absence of fungi in biological specimens, and negative serology or the
presence of low titers of specific antibodies (as determined by the immunodif-
fusion [ID] test).
Fungal isolates, antigen preparations, and gp70 purification. P. brasiliensis
113 (which was originally from the Faculdade de Medicina da Universidade de
Sa˜o Paulo and which was a gift of C. S. Lacaz) was transformed to the yeast
phase, and exoantigen was produced as described by Camargo et al. (7). P.
braziliensis 113 was selected, as previous studies have shown that it produces
large amounts of gp70. The yeast cells were harvested from this growth, washed
three times with lysing buffer (0.05 mM Tris-HCl, 5 mM EDTA), and resus-
pended in 50 ml of the same buffer. Yeast cells were broken with glass beads
(diameter, 425 to 600 m; Sigma) in a vortex mixer. A mixture of protease
inhibitors containing 1 mM phenylmethylsulfonyl fluoride (Sigma) and 1 mM
EDTA was added four times during the process. The homogenate was then
centrifuged at 13,000  g for 30 min at 4°C. The supernatant (which contained
the cytoplasmic antigen) was recovered and used for gp70 purification. The
cytoplasmic yeast antigen was fractionated by gel filtration chromatography with
Sephadex G-50 resin (Pharmacia). The eluted fractions containing the gp70
molecule were concentrated and further purified by gel filtration on a HiTrap
S-200 column (Pharmacia) to eliminate high-molecular-mass contaminants. The
protein concentration was determined by the method of Bradford (4). To verify
the real purification of gp70, the material was monitored by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), silver staining, and
immunoblotting assays.
MAb production and immunization protocols. In the first schedule of immu-
nization, 6-week-old BALB/c mice were injected intraperitoneally with a mac-
erated polyacrylamide gel containing gp70 (gp70 was cut from the SDS-poly-
acrylamide gel) at 2-week intervals for 4 months. In a second schedule, mice were
immunized subcutaneously with 50 g of gp70 (purified through MAbs obtained
in the first fusion) in phosphate-buffered saline (PBS) every 2 weeks. gp70 was
incorporated in Freund’s complete adjuvant in the first injection and in incom-
plete Freund’s adjuvant in the subsequent ones. Injections were always made at
four different sites in the axillary and inguinal regions with a final volume of 100
l per site. Before each immunization, the mice were bled through the ocular
plexus, and the serum was separated by centrifugation and stored at 20°C. The
final immunization was made intravenously 2 days before cell fusion.
Fusion protocols. Cells of murine myeloma line sp2 were fused with spleen
cells from immunized mice by the method of Lopes and Alves (22). For the first
fusion, hybridomas were distributed on 48-well plates (Costar), and at 10 days
postfusion the colonies were screened by immunoblotting, as described below.
For the second fusion, hybridomas were distributed on 96-well plates (Costar),
and screening was performed by an enzyme immunoassay, as described else-
where (18). After the hybridomas were cloned by limiting dilution and expansion
of the positive clones, large amounts of antibodies were obtained from the ascitic
fluid induced in BALB/c mice injected with Pristane (Sigma) before inoculation
of hybridoma cells.
Antibody screening by immunoblotting. Exoantigens were submitted to SDS-
PAGE with 10% acrylamide under reducing conditions, and proteins were then
transferred to nitrocellulose membranes (Sigma). Fragments of nitrocellulose
membranes containing gp70 were cut into small pieces and distributed in 48-well
plates (Costar). After the free sites were blocked with PBS containing 5% skim
milk, 200 l of the supernatants from the hybridoma cultures was added to each
well. After 1 h of incubation at room temperature, the wells were washed five
times for 5 min each time with PBS containing 0.1% Tween 20 (Sigma) (PBS-T)
and treated with affinity-purified peroxidase-conjugated goat anti-mouse immu-
noglobulin (Bio-Rad) for 1 h at room temperature. The wells were again washed
with PBS-T five times. The presence of reactive immunoglobulin G (IgG) was
tested for by the addition of 4-chloro-naphthol in 50 mM Tris buffer (pH 6.8)–
methanol–H2O2, and the IgG was finally washed with distilled water.
Pretreatment of immune sera for use in inh-ELISA. Aliquots of immune
serum, CSF, or BAL fluid (200 l) were mixed with an equal volume of 0.1 M
EDTA (pH 7.2; Sigma) and boiled at 100°C for 3 to 5 min. The tubes were cooled
and centrifuged at 13,000  g for 30 min, and the supernatant was used for the
test.
Inh-ELISA. The inh-ELISA was performed as described previously (19, 25). A
standard inhibition curve was first prepared by adding known concentrations of
gp70 to pooled normal human serum (NHS), CSF, or BAL fluid (a standard
curve was prepared for each biological material) (25). The inhibition reaction
occurred when constant aliquots of anti-gp70 MAb were mixed with the inhibi-
tion standards, PCM patient serum, CSF and BAL fluid samples, and NHS
control samples. These samples were then plated on previously blocked micro-
titer plates (inhibition plates) and incubated overnight at 4°C. The reaction
plates were coated with gp70, incubated overnight at 4°C, and blocked; and
samples from each well in the inhibition plates (containing a mixture of MAb
bound to circulating antigen and free MAb) were transferred to the respective
wells in the reaction plates. The plates were washed and probed with goat
anti-mouse IgG-peroxidase conjugate and developed with a chromogenic sub-
strate, as described previously (19, 25). The optical density (OD) readings at 492
nm were then plotted on a standard curve constructed from the data derived
from MAb titration with the inhibition standards. The antigen concentrations in
serum, BAL fluid, and CSF samples were calculated by using a regression model
constructed with the reciprocal values of the fixed concentrations of gp70 and the
OD values. All of the standards, samples, and controls were tested in duplicate.
The cutoff point was established as the receiver operator characteristic (ROC)
curve.
Statistical analysis. Data were analyzed statistically with Stata software (ver-
sion 7.0 for Windows 98/95/NT, 2001; Stata Corporation, College Station, Tex.),
and specificity and sensitivity were determined by use of the ROC curve. The
inhibition standard curves were constructed in duplicate for at least four inde-
pendent assays. A regression model was constructed with the reciprocal values of
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the antigen concentrations and the OD values obtained. Comparisons were made
by one-way analysis of variance.
RESULTS
MAb production. The anti-gp70 MAb belongs to the IgG1
subclass and recognizes an antigenic determinant of P. brasil-
iensis with a relative molecular mass of 70 kDa. This MAb did
not recognize antigens from Histoplasma capsulatum or Cryp-
tococcus neoformans.
Detection of P. brasiliensis gp70 in serum samples. The stan-
dard curve was obtained by adding increasing concentrations
of gp70 to a pool of control NHS samples. The sensitivity
ranged from 0.001 to 30 g/ml. The cutoff point was estab-
lished from the ROC curve and was based on the antigen
concentration in the sera of patients with PCM and NHS.
Samples with antigen concentrations greater than 1.0 g/ml
were considered positive.
gp70 was detected in 80 of 81 patients (98.76%) with active
PCM (mean concentration, 8.19 g/ml) (Fig. 1). Among this
group, 11 patients presented with the acute form, 6 presented
with the chronic unifocal form, and 63 presented with the
chronic multifocal form; and the mean antigen concentrations
in these three groups were 11.86, 4.83, and 7.87 g/ml, respec-
tively (Fig. 2). Positive results were observed for all patients
with the acute or chronic unifocal form and 98.43% of the
patients with the chronic multifocal form (Table 1). No cross-
reactivity with sera from patients with histoplasmosis or cryp-
tococcosis or NHS was observed. Overall, the sensitivity and
specificity were 98.8 and 100%, respectively.
Detection of P. brasiliensis gp70 in CSF and sera from pa-
tients with neuro-PCM. A standard inhibition curve was con-
structed with known concentrations of gp70 diluted in CSF
from patients with no fungal diseases. The cutoff value was
determined to be 0.21 g/ml for CSF. gp70 was detected in all
CSF samples, and the mean antigen concentration was 6.78
g/ml, showing 100% sensitivity and 100% specificity. Ten of
11 serum samples from patients with neuro-PCM had detect-
able antigen (mean concentration, 3.97 g/ml; cutoff value,
0.97 g/ml) (Table 2 and Fig. 3). No false-positive reactions
with control samples were observed.
Detection of P. brasiliensis gp70 in BAL fluid. A standard
inhibition curve was constructed with known quantities of gp70
diluted in BAL fluid samples from patients with no fungal
diseases. The cutoff level for positivity was established to be
0.46 g/ml. All BAL fluid samples were positive for gp70, and
the mean antigen concentration for this group was 7.5 g/ml.
BAL fluid samples from individuals with no known infectious
diseases were negative for antigen detection (Table 2; Fig. 3).
gp70 antigen clearance during treatment with ITZ. Table 3
shows the initial clinical manifestations of all 23 patients with
PCM as well as the gp70 antigen concentrations obtained for
serum samples collected at the baseline and at the end of
treatment. All 23 serum samples from patients with PCM had
levels of circulating gp70 antigen above the cutoff point at the
time of diagnosis, with a mean antigen concentration of 8.23
g/ml. Antigen levels in serum samples collected at the first
visit after the start of therapy (30 days after the start of anti-
fungal therapy) dropped to a mean concentration of 4.0 g/ml
and further decreased by the 12th month, when the mean
antigen concentration was 0.30 g/ml. Of interest, all but four
FIG. 1. Detection of circulating antigen in sera from patients with
PCM or other mycoses and in NHS by inh-ELISA. Groups studied: 1,
patients with PCM (n  81); 2, patients with cryptococcosis (n  20);
3, patients with histoplasmosis (n  51); 4, NHS (n  93). Bars
represent the mean antigen concentration for each group. The long
fine line represents the cutoff point (1.0 g/ml).
FIG. 2. Detection of circulating antigen in sera from patients with
different forms of PCM by inh-ELISA. Groups studied: 1, patients with
acute form of PCM (n  11); 2, patients with chronic unifocal form of
PCM (n  6); 3, patients with chronic multifocal form of PCM (n 
64). Bars represent the mean antigen concentration for each group.
The long fine line represents the cutoff point (1.0 g/ml).
TABLE 1. Detection of P. brasiliensis 70-kDa circulating antigen in
sera from patients with PCM and other fungal infections and sera
from healthy controls by inh-ELISA
Serum group
No. of serum samples %
Reactive
samples
Mean
antigen
concn
(g/ml)Total Reactive
a Nonreactive
PCM
Acute 11 11 0 100 11.86
Chronic
unifocal
6 6 0 100 4.83
Chronic
multifocal
64 63 1 98.43 7.87
Histoplasmosis 51 0 51 0 0
Cryptococcosis 20 0 20 0 0
NHS 93 0 93 0 0
a A sample was considered positive (i.e., reactive) if the antigen concentration
was 1.0 g/ml.
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serum samples collected at the end of antifungal treatment
showed complete antigen clearance and exhibited negative re-
sults (Fig. 4).
Overall, the patients showed a significant reduction (P 
0.0001) in the levels of circulating gp70 by the third month
after the initiation of therapy, and this reduction was main-
tained until the end of the follow-up period (Fig. 5). All pa-
tients improved clinically and mycologically with therapy. The
antibody titers determined by the ID test at the time of diag-
nosis varied from 1:2 to 1:16, and in almost all patients the
titers decreased during the course of treatment.
DISCUSSION
Since the demonstration of the antigenemia produced in
animals experimentally infected with Streptococcus pneu-
moniae (9), there have been numerous reports on the detection
of antigens in blood, urine, and CSF of patients and animals
infected with bacteria, fungi, viruses, and parasites. In the case
of fungi, with the exception of the capsular polysaccharide of
C. neoformans, which has been detected since 1950 (10), ad-
vances have required sensitive immunoassay procedures that
have become widely applied only recently. In immunocompro-
mised patients with cryptococcosis, histoplasmosis, or aspergil-
losis, the detection of circulating antigens can provide a rapid
diagnosis and prompt treatment in the first days of infection,
when antibodies are not yet produced or are present at low
levels (11, 12). Detection of circulating H. capsulatum antigen
has proved to be useful for the diagnosis and follow-up of
patients with histoplasmosis (42, 43).
Very few techniques have shown high sensitivities and spec-
ificities for antigen detection in biological specimens for the
diagnosis and follow-up of PCM patients. In our previous stud-
ies, we successfully detected gp43 in sera, CSF, and BAL fluid
samples from PCM patients by inh-ELISA, which proved to be
suitable for the monitoring of patients receiving antimycotic
therapy. Go´mez et al. (19, 20) used the inh-ELISA to detect
the 87-kDa molecule in the sera of patients with PCM for both
diagnostic and follow-up purposes. Antibody detection systems
have also been used to assay other molecules for the diagnosis
of PCM, such as a 22- to 25-kDa protein (14), a 58-kDa gly-
coprotein (15), and an 87-kDa protein (8).
In the present study, the overall sensitivity of gp70 detection
among the 81 PCM patients was 98.8% in the presence of a
mean antigen concentration of 8.19 g/ml and reached 100%
in patients with the acute form of the disease, with a mean
antigen concentration of 11.86 g/ml. Among patients with the
chronic form of PCM, antigenemia due to gp70 was observed
in 98.43% of serum samples from patients with the multifocal
form (mean antigen level, 7.87 g/ml); on the other hand, the
sera of 100% of the patients with the chronic unifocal form had
gp70, with a mean antigen concentration of 4.83 g/ml. gp70
was detected in 100% of the CSF and BAL fluid samples, with
mean antigen concentrations of 6.78 and 7.5 g/ml, respec-
tively. No cross-reactions were observed when sera from pa-
tients with other mycoses were tested. The majority (90.9%) of
serum samples from patients with neuro-PCM were positive
for gp70, with a mean antigen concentration of 3.97 g/ml. The
inh-ELISA proved to be helpful in detecting P. brasiliensis
gp70 in biological samples, including BAL fluid and CSF, with
100% sensitivity. Considering the limitations of the conven-
tional methods for the diagnosis of neuro-PCM, our findings
suggest that the gp70 antigen test may be useful for confirma-
tion of the diagnosis in such patients. In addition, the inh-
ELISA has the advantage of being able to process large num-
bers of samples at the same time and presents a high sensitivity
and a high specificity.
For diagnostic purposes, tests based on the ID test are gen-
erally considered to have high specificities; however, false-
FIG. 3. Detection of gp70 antigen in CSF from patients with neuro-
PCM and BAL fluid from patients with pulmonary PCM by inh-
ELISA. Groups studied: 1, CSF of patients with PCM (n 14); 2, CSF
of patients with no fungal disease (n  6); 3, BAL fluid from patients
with PCM (n  23); 4, BAL fluid from patients with no fungal pul-
monary disease (n  10); 5, serum from patients with neuro-PCM (n
 11). Bars represent the average antigen concentration for each
group.
TABLE 2. Detection of P. brasiliensis gp70 antigen by inh-ELISA in various specimens from patients with PCM and their respective controls
Specimen group
No. of serum samples
% Reactive samples Mean antigen concn (g/ml)
Total Reactive Nonreactive
BAL fluid (from patients with PCM)a 23 23 0 100 7.5
CSF (from patients with PCM)b 14 14 0 100 6.78
BAL fluid (control) 10 0 10 0 0
CSF (control) 6 0 6 0 0
Serum from patients with neuro-PCMc 11 10 1 90.9 3.97
a A sample was considered positive (i.e., reactive) if the antigen concentration was 0.46 g/ml.
b A sample was considered positive (i.e., reactive) if the antigen concentration was 0.21 g/ml.
c A sample was considered positive (i.e., reactive) if the antigen concentration was 0.97 g/ml.
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negative results may also occur, and this may be related to the
production of low-avidity IgG2 antibodies directed against car-
bohydrate epitopes (31). The sensitivities of ID test-based tests
range from 65 to 100% (1, 6, 29), depending on the antigen
preparation used. On the other hand, tests with higher sensi-
tivities, such as immunoenzymatic assays, present problems
associated with specificity due to cross-reactivity with heterol-
ogous sera (5, 19).
For many years, assessment of the clearance of the fungal
burden during treatment for PCM has been based on the
detection of antibodies against P. brasiliensis crude or purified
antigens (5, 29, 30, 39). Although healing of apparent fungal
lesions may occur within a short time after antifungal treat-
ment is initiated, long therapeutic courses are desirable in
order to prevent relapses. In this case, the status of the fungal
infection and the host response are usually monitored by indi-
rect methods, in which serology provides information about
the prognosis (5).
Our experience with the follow-up of patients receiving
treatment for PCM has shown that many times the antibody
titers obtained by the ID test do not correlate with the clinical
status of the patient. For example, in some patients elevated
antibody titers (1:64) were observed until the end of treatment,
when the patients were clinically cured. On the other hand,
although for most patients low antibody titers are related to
the absence of clinical symptoms (1:2 or 1:4), in some cases low
titers are present for months and are present in concert with
clinical symptoms. Such discrepancies between the clinical sta-
tus of the host and specific antibody detection are probably
related to the fact that the cell response and not the humoral
response is the main immunologic mechanism able to contain
P. brasiliensis in the infected organism. For these reasons, the
use of serology as a single criterion of cure in patients with
PCM is controversial. In clinical practice, clinical, radiological,
mycological, and serological aspects must be evaluated over a
long period of observation in order to assess the results of
treatment.
Regarding the detection of antigen during treatment,
Mendes-Giannini et al. (28), working with a pool of sera from
patients with PCM using a Western blot assay, observed that
FIG. 4. Mean circulating antigen concentration in sera from pa-
tients with PCM at the time of diagnosis and during the period of ITZ
treatment. Error bars, standard deviation; m, months; n, number of
patients.
TABLE 3. Clinical manifestations and serology results for 23 patients evaluated before and after antifungal treatment
Patient no. and lesion
sitea No. of samples tested
Antigen level (g/ml) at: Antibody titer atb:
Diagnosis First follow-up End of treatmentc Diagnosis End of treatment
1. L, M, LN 8 6.75 5.01 0 (11) 1:8 NDS
2. L, M, LN 7 9.75 15.0 0 (9) 1:4 NR
3. L, M, LN 7 5.64 3.24 0 (9) 1:2 NR
4. L, ORP, LN 9 14.25 9.75 2.16 (12) 1:16 1:4
5. L, S, M, LN 7 13.5 3.39 0 (11) 1:16 1:2
6. L, M, LN 7 9.0 3.59 0 (9) 1:16 1:4
7. L, LN, Lx 6 11.25 1.77 0 (8) 1:4 NDS
8. L, M, LN 7 10.5 3.8 1.69 (9) 1:16 1:4
9. L, M, LN 7 4.16 7.26 0 (11) NR NR
10. L, M 7 7.5 2.67 0 (9) 1:16 1:4
11. L, M, LN 7 9.75 2.74 0 (10) 1:8 1:2
12. L, M, LN 6 4.53 2.37 0 (9) 1:2 NR
13. L, M 6 7.12 3.20 1.03 (9) 1:4 1:2
14. L, M 5 6.94 3.69 0 (9) 1:2 NDS
15. L, M 6 3.57 1.76 0 (8) 1:4 NDS
16. L, M, LN, Lx 6 13.5 2.86 2.24 (9) 1:16 1:4
17. L, M 8 4.94 2.76 0 (10) 1:2 NDS
18. L, M 7 3.57 1.57 0 (10) 1:4 NDS
19. L, Lx 7 8.25 4.18 0 (10) 1:16 1:2
20. L, M 8 10.5 4.09 0 (10) 1:16 1:16
21. L, SNC 6 12.75 3.69 0 (12) 1:16 1:2
22. L, M 8 4.16 1.60 0 (12) 1:4 1:2
23. L, M, LN 7 7.5 2.13 0 (12) 1:4 NDS
Mean 6.91 8.23 4.0 0.30
a L, lung; M, mucosae; LN, lymph nodes; Lx, Larynx; ORP, oropharynx; S, skin; CNS, central nervous system.
b NR, nonreactor; NDS, reactive only with nondiluted serum.
c Values in parentheses are the length of follow-up (in months).
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gp43 started to disappear from the circulation after 10 months
of treatment and was undetectable after 2 years of treatment.
More recently, the same group of investigators (36) detected P.
brasiliensis antigens in 75% of patient urine samples tested by
an indirect competition enzyme immunoassay and by an im-
munoblot test for monitoring the response to therapy.
One of the main goals of the present study was to assess
gp70 antigen clearance during treatment of PCM with ITZ by
comparing the clearance from serum samples collected at the
baseline and after 8 to 12 months of therapy. All 23 patients
selected for the study showed a good clinical response to ther-
apy, with no relapse of fungal disease documented over the
follow-up period. Overall, decreasing levels of P. brasiliensis
gp70 were detected in patients during successful antifungal
therapy. In contrast, the ID test titers of these patients varied
over the follow-up period (1:16 to 1:2). Table 3 shows the
clinical manifestations of PCM in the patients and the corre-
lation between the levels of gp70 antigenemia and the levels of
anti-P. brasiliensis antibody at the time of diagnosis, 1 month
after treatment, and the end of treatment. At the time of
diagnosis, all except one of the patients had detectable gp70
antigen and anti-P. brasiliensis antibodies (one patient had a
negative ID test result). A significant decrease in gp70 titers
occurred during the first month of therapy in 22 patients; at the
end of therapy, only 4 (17.39%) patients (patients 4, 8, 13, and
16) had detectable gp70 antigen (antigen levels, 2.5 g/ml)
and positive titers by the ID test.
By the end of the follow-up period, antibody titers were
negative in three patients (patients 2, 3, and 12), and one
patient (patient 9) had undetectable antibodies (by the ID test)
from the time of diagnosis to the end of treatment. However,
the antigen level was also negative until the end of follow-up.
Once the levels of gp70 decreased, gp70 persisted at low levels
in serum until the end of therapy. On the other hand, in
various patients, the antibody titers seemed to decrease a little
later, after about 6 months of therapy. Of particular note is the
common persistence of antibodies for a considerable period of
time even after the cessation of an apparently successful course
of treatment.
Decreased levels of antigenemia were observed in two pa-
tients after 6 months of ITZ treatment, but their anti-P. bra-
siliensis antibody titers remained high (1:16) and did not
change throughout the period of treatment (patient 20). On
the other hand, patient 9 had undetectable antibodies from the
time of diagnosis to month 11 of treatment but had a substan-
tial decrease in antigenemia levels during treatment with ITZ.
All PCM patients showed clinical improvement after the pe-
riod of antifungal therapy (8 to 12 months).
In conclusion, our results indicate that the detection and
quantification of P. brasiliensis gp70 antigen in serum by inh-
ELISA is a sensitive method for the diagnosis of PCM and may
be used to evaluate patients for the clearance of the fungal
burden during treatment. Moreover, the high sensitivity of this
assay for the detection of gp70 in different biological fluids
opens a new possibility for the diagnosis of PCM in patients for
whom conventional methods present limitations.
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